Literature DB >> 16880070

Probiotics in the prevention and treatment of gastrointestinal infections.

Elizabeth S Huebner1, Christina M Surawicz.   

Abstract

Probiotics have been studied in a variety of GI infections, and are an appealing concept given their favorable safety profiles. Several placebo-controlled trials indicated that lactobacilli have a suppressive effect on H pylori infection. Although some studies reported improvement in H pylori eradication, others failed to confirm this. Controlled trials support the use of Lactobacillus GG and S boulardii for the prevention of AAD, and have demonstrated the effectiveness of S boulardii as adjunctive therapy for RCDAD. Several placebo-controlled trials showed a reduction in the severity and duration of acute diarrhea in children with use of Lactobacillus GG. Studies of probiotics for the prevention of traveler's diarrhea yielded conflicting results, and their routine use cannot be recommended in this setting. Preliminary evidence suggests a potential role for reducing secondary pancreatic infections, although conclusive evidence is not available at this time. Additional clinical trials are indicated to define the role of probiotics further before wide-spread use can be recommended.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880070     DOI: 10.1016/j.gtc.2006.03.005

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  15 in total

1.  The angiogenic effect of probiotic Bacillus polyfermenticus on human intestinal microvascular endothelial cells is mediated by IL-8.

Authors:  Eunok Im; Yoon Jeong Choi; Cho Hee Kim; Claudio Fiocchi; Charalabos Pothoulakis; Sang Hoon Rhee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11       Impact factor: 4.052

2.  Diarrhoea associated with antibiotic use.

Authors:  Lynne V McFarland
Journal:  BMJ       Date:  2007-07-14

3.  The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition.

Authors:  Elise L Ma; Yoon Jeong Choi; Jinyoung Choi; Charalabos Pothoulakis; Sang Hoon Rhee; Eunok Im
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

Review 4.  Probiotic products in Canada with clinical evidence: what can gastroenterologists recommend?

Authors:  G Reid; K Anukam; T Koyama
Journal:  Can J Gastroenterol       Date:  2008-02       Impact factor: 3.522

5.  Effect of molecules secreted by Lactobacillus acidophilus strain La-5 on Escherichia coli O157:H7 colonization.

Authors:  Maira J Medellin-Peña; Mansel W Griffiths
Journal:  Appl Environ Microbiol       Date:  2008-12-16       Impact factor: 4.792

6.  Evaluation of reuterin production in urogenital probiotic Lactobacillus reuteri RC-14.

Authors:  Peter Cadieux; Anette Wind; Philip Sommer; Laura Schaefer; Kate Crowley; Robert A Britton; Gregor Reid
Journal:  Appl Environ Microbiol       Date:  2008-06-06       Impact factor: 4.792

7.  Bacillus polyfermenticus ameliorates colonic inflammation by promoting cytoprotective effects in colitic mice.

Authors:  Eunok Im; Yoon Jeong Choi; Charalabos Pothoulakis; Sang Hoon Rhee
Journal:  J Nutr       Date:  2009-08-12       Impact factor: 4.798

8.  Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function.

Authors:  K C Johnson-Henry; K A Donato; G Shen-Tu; M Gordanpour; P M Sherman
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

9.  L. plantarum prevents enteroinvasive Escherichia coli-induced tight junction proteins changes in intestinal epithelial cells.

Authors:  Huanlong Qin; Zhongwei Zhang; Xiaomin Hang; Yanqun Jiang
Journal:  BMC Microbiol       Date:  2009-03-31       Impact factor: 3.605

10.  Probiotics for the treatment of pediatric helicobacter pylori infection: a randomized double blind clinical trial.

Authors:  Khodadad Ahmad; Farahmand Fatemeh; Najafi Mehri; Shoaran Maryam
Journal:  Iran J Pediatr       Date:  2013-02       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.